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Lloyd M. Taylor, Jr., MD and John M. Porter,  MD, Portland, Ore. 
Purpose: Knowledge of the long-term clinical outcome of Raynaud's yndrome (RS), 
essential both for patient counselling and formulation of optimal therapeutic recommen- 
dations, is conspicuously deficient in current medical iterature. We have prospectively 
monitored 1039 patients with RS, 118 (11.4%) for more than 10 years to determine 
whether initial characterization was able to predict outcome. 
Methods: At initial presentation, patients were divided into four groups on the basis of 
vascular laboratory and serologic testing results: vasospastic, serologically positive 
(spast, sero+) and negative (spast,sero-) and obstructive, serologically positive 
(obst,sero + ) and negative (obst,sero-). 
Results: Connective tissue disease (CTD) was present initially in 48.6% of patients with 
spast, sero + results and 72.9% of patients with obst, sero + results. Of the remaining 
patients in these groups, progression to CTD during follow-up occurred in 16.4% of 
patients with spast,sero + results and 30.4% of patients with obst,sero + results. In the 
> 10-year follow-up group, progression to CTD occurred in 81.8% of patients in the 
obst,sero + group. Progression to CTD occurred in 2.0% of patients in the spast,sero- 
group and 8.5% of patients in the obst, sero- group. Digital ulcers occurred in 15.5% of 
patients in the spast, sero + group, 5.2% of patients in the spast, sero-  group, 55.6% of 
patients in the obst, sero + group, and 48.2% of patients in the obst, sero- group. Digital 
or phalangeal amputations were required in 1.4%, 1.6%, 11.6%, and 19.0% of these 
patients, respectively. 
Conclusions: The long-term outcome of patients with RS can be predicted by initial 
serologic studies and separation into vasospastic and obstructive categories. Initial 
serologic positivity strongly predicts the development ofCTD. Initial vascular laboratory 
classification ofobstructive RS strongly predicts digital ulcerations, which occurred in half 
of these patients regardless of initial serologic study results. Amputations were required 
in 10% to 20% of patients with obstructive RS. These occurrences did not increase with 
increased uration of disease. Ulcerations and amputations were rare in patients initially 
with vasospastic KS. (J VASC SURG 1996;23:76-86.) 
Digital pain and blanching caused by exposure to 
cold and .emotional stress was first described by 
Raynaud ~ in 1862. In spite of more than a century of 
study, Raynaud's syndrome (RS) remains asubject of 
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considerable speculation but only modest data. In 
spite of numerous publications concerning cause, 
diagnosis, pathophysiology, and natural history, each 
remains substantially unknown. "A particular defi- 
ciency is the substantial absence of information 
concerning the long-term outcome of  patients with 
RS. Clearly, over time, some patients with RS have 
development of diagnosable connective tissue dis- 
eases (CTD), digital ulcerations, and require digital 
amputations, whereas others pursue a benign course, 
with their RS amounting to little more than a 
nuisance condition consisting of occasional finger 
discomfort with exposure to cold or emotional stress. 
The course of an individual patient's disease to date 
has been generally unpredictable. 
The ability to predict the clinical outcome of 
patients at initial presentation would be extremely 
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valuable from a prognostic standpoint. Patients 
predisposed to a more benign course would benefit 
from reassurance, whereas knowledge of a more 
serious prognosis would allow the remainder to 
regard the syndrome with appropriately increased 
vigilance. We have reviewed our experience with 
long-term outcome of 1039 prospectively monitored 
patients with RS in an effort to identify prognostic 
variables on presentation. 
METHODS 
At the Oregon Health Sciences University, we 
have held a weekly clinic devoted to RS since 1971. 
Between 1971 and 1995, 1039 patients with RS 
were enrolled in this clinic. Initial evaluation con- 
sisted of history, physical examination, hand radiog- 
raphy, serologic testing, and noninvasive vascular 
laboratory testing. Patients were questioned specifi- 
cally about onset of symptoms, inciting factors, 
history of ulcerations, and smoking history. Patients 
were asked to characterize sites of involvement, hat 
is, hands, feet, or both. Pertinent historical data 
including frostbite, trauma, carpal tunnel syndrome, 
Buerger's disease, atherosclerosis, vibration expo- 
sure, kidney disease, malignancy, medication, and 
endocrine abnormalities were recorded. Patients 
were questioned with regard to symptoms of CTD, 
including arthralgias, dysphagia, and sclerodactyly. 
Hand radiograms were reviewed to determine calci- 
nosis or tuft resorption. 
The minimal baseline serologic examination con- 
sisted of rheumatoid factor and anti-nuclear anti- 
body. Further serologic testing included extractable 
nuclear antigen, anti-ribonucleoprotein, anti-single- 
strand-B, and anti-native-DNA as necessary to es- 
tablish the diagnosis of a CTD. In addition, a 
complete blood count, sedimentation rate, and se- 
rum protein electrophoresis were obtained, and in 
recent years a~ hypercoagulable screen was obtained 
in selected patients consisting of protein C, protein 
S, lupus anticoagulant, antithrombin III, antiphos- 
pholipid antibody, and recently factor V resistance 
to activated protein C. Assays for cold agglutinins, 
cryoglobulins, and cryofibrinogens were also per- 
formed on selected patients. Patients were consid- 
ered to have a hematologic abnormality if the results 
of any of the above tests, except he serologic tests, 
were abnormal. When CTD was suspected, rheu- 
matologic consultation was obtained and appro- 
priate specific tests were performed to permit CTD 
diagnosis according to American Rheumatologic 
Association criteria. 2-7 
The standard noninvasive vascular laboratory 
approach as changed uring the course of this study. 
Between 1972 and 1978 the standard evaluation 
consisted of hand temperature recovery after cold 
water immersion and finger plethysmography as 
previously described. 8 Although close to 100% 
specific, the cold water test was only 50% sensitive. 
Since 1978, patients have undergone a hypothermic 
challenge with finger blood pressure measurements 
according to the method described by Nielsen. 9This 
method is 87% specific and 90% sensitive, with an 
overall accuracy of 92% in our experience) ~ 
The diagnosis of RS was based on the patients' 
symptoms of digital color change and coolness with 
cold exposure or emotional stress confirmed by a 
positive Nielsen test result, although a positive 
Nielsen test result was not required for entry into the 
study population. In addition to the Nielsen test, all 
patients underwent measurement of finger systolic 
blood pressures and finger plethysmography. Mea- 
surement of finger blood pressures was performed in 
a warm, draft-free room. A pneumatic uffwas placed 
around the proximal phalanx, with a photoplethys- 
mograph placed over the distal phalanx. Values 
obtained reflect the pressure in the common and 
proximal proper digital arteries. The pulse contour 
was evaluated with photoplethysmography as previ- 
ously described. 11 Representative normal and ob- 
structive waveforms are displayed in Fig. 1. 
On the basis of the results of their noninvasive 
studies, patients were characterized as having vaso- 
spastic or obstructive RS. The distinction between 
vasospastic and obstructive RS was made at room 
temperature. Most patients with RS experienced an 
abnormal digital pressure drop with the Nielsen test. 
Measurement of digital artery pressures and digital 
plethysmography at room temperature distinguished 
obstructive RS from vasospastic RS. A positive 
Nielsen test result, blunted or peaked waveforms on 
plethysmography, and digital artery systolic pressures 
more than 20 mm Hg below brachial pressure 
established the diagnosis of obstructive RS.~,~2 
During the early 1970s hand arteriography was 
part of our routine evaluation) a We have since 
modified this approach and now obtain upper 
extremity angiograms only on patients in whom 
there is a suspicion of a proximal arterial lesion, 
particularly in patients with unilateral symptoms and- 
no evidence of a systemic disorder. 14 
On the basis of initial evaluation, patients were 
categorized into four groups depending on their 
initial serologic and noninvasive study results: (1) 
vasospastic, serologically positive (spast,sero + ); (2) 
vasospastic, serologically negative (spast,sero - ); (3) 
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Fig. 1. Diagrammatic photoplethysmographic waveforms demonstrate (A) normal and (B) 
obstructive patterns9 
obstructive, serologically positive (obst,sero + ); and 
(4) obstructive, serologically negative (obst,sero - ). 
At least one positive serologic test result (anti-nuclear 
antibody or rheumatoid factor) was required to be 
considered serologically positive. Patients were 
monitored annually. History, physical examination, 
serologic studies, and noninvasive vascular studies 
were obtained at the annual visits. Patients were 
evaluated for the development of  CTD or other 
associated diseases, digital ulcerations, and digital 
amputations. Length o f  fol low-up was determined 
from the date o f  the patients' initial visit, not from 
their subjective recollection o f  the date o f  onset o f  
their symptoms. 
Statistical methods .  Comparisons between 
groups were performed with chi-squared analysis for 
qualitative variables and the Student test for quanti- 
tative variables. 
RESULTS 
Length  o f  o l low-up.  Between 1972 and 1994, 
1039 patients with RS were evaluated in our 
Raynaud's clinic. Mean length of  fol low-up for the 
entire group was 3.2 years (range 0 to 21 years). One 
hundred eighteen (11.4%) were monitored for 10 
years or more. The demographics of  these two 
groups are presented in Table I. No  differences were 
present in age, sex distribution, smoking history, 
diabetic status, or sites of  involvement. 
Type  o f  RS. Five hundred eighty-five patients 
(56.3%) were diagnosed as having vasospastic RS. 
Four hundred fifty-four patients (43.7%) were diag- 
nosed as having obstructive RS. In the > 10-year 
fol low-up group, 50 patients (42.4%) had vasospas- 
tic RS, and 68 (57.6%) had obstructive RS. Three 
hundred forty-nine patients (33.6%) had initially 
serologically positive results. Six hundred ninety 
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Table I. Patient demographics: all patients 
compared with patients monitored for more 
than 10 years 
All 
(n = lO3O) 
> 10 yrs 
follow-up 
(n = H8) 
Mean age 43.0 -+ 16.0 41.0 -+ 13.7 
Sex (F/M) 682/357 85/33 
Smoker (y/n/ex) 335/491/160 36/59/23 
Diabetes (n/y) 983/31 110/8 
Sites of involvement 655/80/301 80/6/32 
.(hands~feet~both) 
F/M, Female/male; y/n/ex, yes/no/former; n/y, no/yes. 
p = ns between all and more than 10 years follow-up. 
patients (66.4%) had initially serologically negative 
results. In the > 10-year follow-up group, 58 patients 
(49.2%) had initially positive serologic results, and 
60 (51.8%) had initially negative serologic results. 
Patients were divided into four groups on the 
basis of vasospastic or obstructive RS and the 
presence or absence of initially positive serologic 
results. The classifications of the whole group and the 
> 10-year follow-up group are shown in Table II. 
The most frequent classification among all patients 
was spast,sero- (42.6%). This classification was 
statistically less frequent in the > 10-year follow-up 
group (27.1%). In contrast, the obst,sero+ group, 
which represented 19.9% of all patients at presenta- 
tion, was statistically more frequent in the > 10-year 
follow-up group (33.9%). The percentages of pa- 
tients in the spast,sero + and obst,sero - groups were 
not different between all patients and the > 10-year 
follow-up group (13.7% vs 15.3% and 23.8% vs 
23.7%, respectively). 
The demographics of all patients in the four 
groups are shown in Table III. Patients in the 
spast,sero- group were younger (p < 0.001) at the 
time ofpresontation than all other groups. A greater 
percentage of male patients (p < 0.001) were 
present in the obst, sero- group compared with all 
other groups. A higher percentage of smokers was 
present in the two groups with obstructive RS 
compared with those with vasospastic RS (p < 
0.05). Sites of involvement also differed between 
these groups (p < 0.05). Differences were also 
noted in mean length of follow-up, with the shortest 
length of follow-up in the spast, sero- group 
(2.7 _+ 3.9 years), the longest follow-up in the 
obst,sero + group (4.5 __ 5.4 years), and intermedi- 
ate length of follow-up in the spast, sero + (3.2 _+ 4.5 
years) and obst,sero- (3.4 -+ 4.9 years) groups. 
Table II. Initial group classification of 
patients with RS 
> I0 yrs 
Initial All follow-up 
classification (n = 1039) (n = 118) 
Spast, sero - *  443 (42.6%) 32 (27.1%) 
Spast, sero + 142 (13.7%) 18 (15.3%) 
Obst, sero - 247 (23.3%) 28 (23.7%) 
Obst, sero + ~ 207 (23.8%) 40 (33.906) 
*p < 0.005 between all and more than 10 years follow-up. 
In the > 10-year follow-up group (Table IV), the 
same sex differences were present between the 
obst, sero - group and all other groups (p < 0.05). A 
difference in age was present only between the 
spast,sero+ and spast, sero- groups (p < 0.05). 
More smokers were present in the obst,sero - group 
compared with both groups with vasospastic RS 
(p < 0.01). Sites of involvement differed between 
the obst,sero- group and the groups with positive 
serologic results (p < 0.05), who were more likely to 
have involvement of both hands and feet. Length of 
follow-up differed only between the spast,sero- 
group and the obst,sero- group (p < 0.05). 
CTD present at the time of diagnosis. At the 
time of initial diagnosis of RS, 48.6% of patients in 
the spast,sero + group and 72.9% of patients in the 
obst, sero + group were diagnosed with CTD (Table 
V). These percentages are the same among the 
comparable groups of patients in the < 10-year 
follow-up group (50.0% and 72.5%, respectively). 
Development ofa CTD during follow-up. The 
percentages of patients without a CTD at initial 
presentation who went on to have development of a 
CTD are presented in Table VI. This least frequent 
rate of progression to CTD was in the spast,sero- 
group (2.0%), with the highest in the obst, sero+ 
group (30.4%). CTD developed in 16.4% of patients 
in the spast,sero+ group and 8.5% of patients 
without an initial CTD in the obst,sero- group. A 
statistically significant difference in the rate of pro- 
gression was present among all groups except spast, 
sero + vs both groups with obstructive RS. 
Of patients monitored for more than 10 years, 
81.8% of the obst,sero + group withqut initial CTD 
had development of a CTD, an incidence that 
exceeded the group as a whole (p < 0.005). Pro- 
gression to CTD occurred in 33.3% of patients in the 
spast,sero+ group, 17.9% of patients in the obst, 
sero- group, and 6.3% of patients in the spast, 
sero- group. No further differences were present 
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Table I lL Patient demographics: allpatients 
Initial classification Age (yrs.)* Sex (F/M) ~ Smoking (y/n/ex)$ Sites (h/fib)#: LOF (yrs.)w 
Spast, sero -  39.3 -+ 15.1 315/128 112/245/53 250/37/154 2.7 + 3.9 
Spast, sero + 44.2 + 14.9 113/29 28/86/21 87/6/49 3.2 -+ 4.5 
Obst, sero -  45.3 _+ 14.9 98/149 130/61/48 164/33/50 3.4 _+ 4.9 
Obst, sero+ 47.2 -+ 20.0 156/51 65/99/38 154/4/48 4.5 + 5.4 
F/M, Female/male; y/n/ex, yes/no/former; h/J~b, hands/feet/both. 
*p < 0.001 all groups compared to A. 
tp < 0.001 all groups compared to C. 
Sp < 0.05 between all groups except A to B. 
w < 0.05 between all groups except A to B and A to C. 
Table IV. Patient demographics: > 10-year follow-up group 
Initial classification Age (yrs.)* Sex (F/A4)~ Smoking (y/n/ex)$ Sites (h/f/b)w LOF (yrs.)] I 
Spast, sero -  37.7 -+ 14.2 29/3 6/19/7 19/2/11 13.0 -+ 2.8 
Spast, sero+ 46.0 -+ 10.3 14/4 2/13/3 11/0/7 14.2 +- 2.8 
Obst, sero -  40.6 -+ 14.8 11/17 16/8/4 21/4/3 14.7 +- 2.9 
Obst, sero+ 41.7 -+ 14.1 30/10 13/19/8 30/0/10 14.0 -+ 3.1 
F/M, Female/male; y/n/ex, yes/no/former; h/Jfb, hands/feet/both. 
*p < 0.05 between A and B. 
#p < 0.05 all groups compared to C. 
Sp < 0.05 A and B compared to C. 
w < 0.05 B and D compared to C. 
liP < 0.05 between A and C. 
Table V. CTD present at initial diagnosis 
of RS 
Initial classification All* > lO yrs. follow-up~ 
Spast, sero -  0/443 (0%) 0/32 (0%) 
Spast, sero + 69/142 (48.6%) 9/18 (50%) 
Obst, sero - 0/247 (0%) 0/28 (0%) 
Obst, sero + 151/207 (72.9%) 29/40 (72.5%) 
*p < 0.0005 between all groups except A to C. 
tp < 0.0005 between all groups except A to C, B to D. 
Table VI. CTD development during 
follow-up 
Initial classification All* > 10 yrs. follow-upt 
Spast, sero -  9/443 (2.0%) 2/32 (6.3%) 
Spast, sero + 12/73 (16.4%) 3/9 (33.3%) 
Obst, sero - 21/247 (8.5%) 5/28 (17.9%) 
Obst, sero +~ 17/56 (30.4%) 9/11 (81.8%) 
up < 0.0005 between all groups except B to C and B to D. 
tp < 0.001 between A to D and C to D. 
~p < 0.005 between all and more than 10 years follow-up. 
between the whole group and the long-term 
follow-up group. 
Overall prevalence of CTD. Overall, CTD were 
diagnosed either initially or during follow-up in 279 
patients (26.9%). Within the four groups, CTD were 
diagnosed in 81.1% of patients in the obst,sero+ 
group, 57.0% of patients in the spast,sero + group, 
8.5% of patients in the obst,sero-, and 2.0% of 
patients in the spast,sero- group (Fig. 2). Statisti- 
cally significant differences were present among all 
groups (p < 0.001). 
In the > 10-year follow-up group, CTD were 
diagnosed in 57 patients (48.3%). This included 
95% of patients in the obst,sero + group, 66.7% of 
patients in the spast,sero + group, 17.9% of patients 
in the obst, sero- group, and 6.3% of patients in the 
spast,sero - group (Fig. 3). Differences were present 
among all groups (p < 0.05) except between the two 
serologically negative groups. 
Types of CTD. Of the 279 patients diagnosed 
with CTD, 186 had obstructive RS, which represents 
43.2% of the total number of patients with obstruc- 
tive RS. The remaining 93 patients had vasospastic 
RS, representing 16.4% of the total number of 
patients with vasospastic RS. The distribution of the 
types of CTD diagnosed is presented in Table VII. 
Progressive systemic sclerosis (scleroderma) was the 
single most frequent CTD in patients with oBstruc- 
tive RS, whereas Sj6gren's yndrome and undiffer- 
entiated CTD were comparatively more frequent in 
patients with vasospastic RS (p--0.013, and 
p -- 0.009, respectively) with a trend for increased 
incidence of systemic lupus erythematosus 
(p -- 0.094). No differences in mixed CTD, rheu- 
matoid arthritis, or unknown CTD were present. 
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Fig. 3. Percentages of patients monitored more than 10 years (n = 118) who were diagnosed 
with CTD either initially (dark bar) or during follow-up (gray bar). 
Deve lopment  of digital ulcerations. The per- 
centage of patients in each of the four patient groups 
with digital ulceration is presented in Table VIII. 
Ulcerations were distinctly infrequent in patients in 
the spast,sero- group, occurring in only 23 of 443 
patients (5.2%). A history of atherosclerosis, Buerg- 
er's disease, frostbite, a hematologic abnormality, or 
trauma was present in 10 of these patients. No 
associated disease was detected in the other 13 
patients. Digital ulceration was most frequently 
present at the time of presentation, with approxi- 
mately one half of patients having recurrent ulcer- 
ation during follow-up. ~s 
Digital ulcerations were also infrequent in pa- 
tients in the spast,sero + group, occurring in 22 of 
la8 patients (15.9%). CTD was presenf in 18 of 
these patients. In the remaining Ibur patients, either 
Buerger's disease, frostbite, or a hematologic abnor- 
mality was present. 
Digital ulcerations occurred in 119 of 247 
(48.2%) patients in the obst, sero-  group. Associ- 
ated diseases in this group included atherosclerosis in 
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Table VII. Types of CTD in patients with 
vasospastic and obstructive RS 
Vasospastic Obstructive 
CTD (n = 90) (n = 189) Significance 
MixedCTD 11 (12.2%) 22 (11.6%) 
Progressive systemic 19 (21.1%) 109 (57.7%) p < 0.0005 
sclerosis 
Rheumatoid arthritis 8 (8.9%) 13 (6.9%) 
Sj6gren'ssyndrome 14 (15.6%) 10 (5.3%) p < 0.05 
Systemic lupus 13 (14.4%) 14 (7.4%) p = 0.094 
erythematosus 
Undifferentiated 19 (21.1%) 16 (8.5%) p < 0.01 
CTD 
Unknown CTD 6 (6.7%) 5 (2.6%) 
Table VIII. Presence of digital ulcerations 
Initial classification All* > 10 yrs. follow-upt 
Spast, sero -  23/443 (5.2%) 2/32 (6.3%) 
Spast, sero + 22/142 (15.5%) 5/18 (27.7%) 
Obst, sero - 119/247 (48.2%) 15/28 (53.6%) 
Obst, sero + 115/207 (55.6%) 21/40 (52.5%) 
*p < 0.001 between all groups except C to D. 
lp < 0.001 between A to C and A to D. 
20 patients, Buerger's disease in 24, a hematologic 
abnormality in 16, rapid onset digital artery occlu- 
sion as a result of hypersensitivity angiitis or emboli 
from a proximal source in 12, and a history of 
frostbite in 6. Ten patients had a history of either 
malignancy, carpal tunnel syndrome, trauma, or 
vibration exposure. No cause was recognized in the 
remaining 31 patients. 
One hundred fifteen of 207 (55.6%) patients in 
the obst,sero + group had development of ulcers. 
Ninety-six of these (83.5%) had a CTD. Nineteen 
(16.1%) had positive serologic results only without 
evidence of CTD. Associated iseases were present in 
19 of the 96 patients with CTD (carpal tunnel 
syndrome in six, hypothyroidism in five, cancer in 
four, atherosclerosis, hematologic abnormality, frost- 
bite, and trauma in one each). Nine of the 19 with 
positive serologic results only had associated diseases 
(rapid onset digital artery occlusion, hematologic 
abnormality, and atherosclerosis in two each, carpal 
tunnel syndrome, hypothyroidism, and Buerger's 
disease in one each). 
Differences were present among each of the four 
groups (p < 0.001) except obst,sero+ versus obst, 
sero - - .  
In the group of patients monitored greater than 
10 years, digital ulcers occurred in 27.7% of patients 
in the spast, sero+ group, 6.3% of patients in the 
spast,sero, group, 52.5% of patients in the obst, 
sero+ group, and 53.6% of patients in the obst, 
sero-.  Differences were present between the spast, 
sero - group versus both groups with obstructive RS 
(p < 0.001). No differences inulcer prevalence were 
present in any of the four patient groups when the 
whole group was compared with the > 10-year 
follow-up group. 
Digital or phalangeal mputations. Digital or 
phalangeal mputations (Table IX) were rarely re- 
quired in patients with vasospastic RS. Only 1.4% of 
patients in the spast,sero+ group and 1.6% of 
patients in the spast,sero- group required amputa- 
tions, with no difference between these groups. 
Amputations were required in 11.6% of patients in 
the obst, sero + group and 19.0% of patients in the 
obst,sero- group. Again, no difference was present 
between these groups. Statistical significance was 
achieved (p < 0.005) when either of the groups with 
vasospastic RS was compared with either of the 
groups with obstructive RS. 
In the > 10-year follow-up group, amputations 
were required in none of the patients in the spast, 
sero+ group, 6.3% of the patients in the spast, 
sero- group, 20.0% of the patients in the obst, 
sero+ group, and 25.0% of the patients in the 
obst, sero- group. Although there was a trend 
toward more amputations in the patients with 
obstructive RS, no comparisons reached statistical 
significance. Likewise, no differences were present 
among all patients and the > 10-year follow-up 
group for any of the four patient categories. Unlike 
ulceration, amputation was rarely performed at 
admission to the study but frequently was performed 
within 1 year of study initiation. 
DISCUSSION 
RS remains an enigmatic medical condition 
despite more than a century of research on this 
subject. RS is estimated to affect between 3.5% and 
25% of the male population and between 5% and 
30% of the female population in cool, damp 
climates,9-~2 and it is frequently encountered bymany 
physicians, including vascular surgeons. 1619 Our 
interest in this condition has resulted in the accumu- 
lation of a database of more than 1000 patients over 
a 24-year period representing a broad specti-um of 
disease severity. In this study we have attempted to
characterize the long-term clinical outcome of these 
patients and, on the basis of an initial evaluation 
including both vascular laboratory and serologic 
data, to establish the predictive likelihood of disease 
progression, including CTD, digital ulcerations, and 
digital amputations. 
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Our method of classification of RS differs from 
the traditional system established in the 1930s by 
Allen and Brown 2~ who divided RS into Raynaud's 
phenomenon and Raynaud's disease on the basis of 
the absence or presence of an associated isease. 
However, as early as the 1950s, it was recognized that 
Raynaud's phenomenon may precede an underlying 
disease by many yearsfl 1 Thus from a prognostic 
standpoint the traditional classification is of limited 
use, and we have chosen to classify all patients with 
cold- o/" stress-induced digital ischemia s having RS. 
Nonetheless, it is clear that all patients diagnosed 
with symptoms of digital ischemia re not the same, 
and important distinctions are helpful, ideally at the 
time of initial diagnosis. We have divided patients 
into four groups according to whether they have 
evidence of digital vasospasm or obstruction and 
whether they have positive or negative serologic 
results. 
The most frequent group in the overall database 
were patients with negative serologic results and 
digital artery vasospasm. In the > 10-year follow-up 
group, however, patients with obstructive symptoms 
and positive serologic results were more frequent. 
This is explained in part by differences in disease 
severity. Patients in the spast,sero- group typically 
have less severe disease and are therefore l ss likely to 
return for long-term follow-up, whereas in the 
obst,sero + group the opposite holds true. 
The association between RS and the subsequent 
development of a CTD has been well established for 
years. Gifford and Hines, 2~ reporting on their expe- 
rience from the Mayo Clinic in the 1950s, found a 
4.6% progression to a CTD in 280 patients moni- 
tored for more than 2 years; however, no subclassi- 
fication of RS was done. Several recent smaller 
studies have addressed the likelihood of CTD devel- 
opment in patients with RS. In patients with no 
clinical or serologic abnormalities, progression to 
CTD occurred in up to 9% in series consisting of 16 
to 78 patients with mean follow-up of 2 to 6 
years. 22-s~ The corresponding group in our study was 
the spast,sero - group, consisting of 443 patients, 32 
of whom were monitored greater than 10 years. 
Progression to a CTD occurred in 2% of the whole 
group and 6.3% among those monitored greater 
than 10 years, which is consistent with prior studies 
of patients with RS. 
The risk of a subsequent diagnosis of a CTD in 
patients with RS and one or more serologic or clinical 
abnormalities i more variable. In studies ranging 
from nine to 35 patients, progression to a CTD 
ranged from 11% to 65%. ls-2s In our study the rate 
Table IX. Requirement for digital or 
phalangeal mputations 
Initial classification All ~ > lO yrs. follow-up~ 
Spast, sero - 7/443 (1.6%) 2/32 (6.3%) 
Spast, sero + 2/142 (1.4%) 0/18 (0%) 
Obst, sero - 47/247 (19.0%) 7/28 (25.0%) 
Obst, sero + 24/207 (11.6%) 8/40 (20.0%) 
~p < 0.005 between all groups except A to B, C to D. 
tp = ns between all groups. 
of progression depended on the nature of the initial 
abnormality. Two hundred forty-seven patients, 28 
monitored more than 10 years, had clinical evidence 
of digital obstruction at the time of diagnosis without 
serologic abnormality; 8.5% of this group and 17.9% 
of the long-term follow-up group went on to have 
development of a CTD. The rate of progression is
much greater if initial serologic results are positive. In 
the 142 patients with vasospastic RS and positive 
serologic results, 48.6% had a CTD at the time of 
diagnosis, and of the remaining patients, 16.4% of 
the entire group and 33.3% of the long-term 
follow-up group went on to have development of 
CTD. Patients with obstructive RS and positive 
serologic results had a 72.9% prevalence of CTD 
initially. Of the remaining 27.1%, 30.4% of the 
whole group and 81.8% of the long-term follow-up 
group went on to have development of CTD. 
Very few studies have addressed the issue of 
progression to ulcerations and amputations in pa- 
tients with RS. In an initial study from our institution 
of 44 patients monitored more than 10 years with 
evidence of digital artery obstruction documented by 
angiography at the time of presentation, 58% of 
patients with initial ulcerations had development of
recurrent ulcerations, and 15% required amputa- 
tions. 24 
It is generally believed that primary vasospastic 
RS is a benign disease constituting little more than a 
nuisance condition. Our study generally supports this 
view. In the 443 patients in the spast,sero- group, 
digital ulcerations developed in 5.2% (6.3% in the 
long-term follow-up group), and amputations were 
required in 1.6% of patients (6.3% in the long-term 
follow-up group). Given the benign nature, of this 
disease, it was surprising that ulcers or "amputations 
occurred in any of this subset. However, further 
analysis revealed that most of this small group 
proceeded to have development of conditions asso- 
ciated with digital artery obstruction, that is, athero- 
sclerosis and Buerger's disease, which may have been 
undetectable by vascular laboratory evaluation. 
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Again, in patients with serologic or vascular 
laboratory abnormalities, progression to ulcers and 
amputations depended on the nature of the abnor- 
mality. Patients with vasospastic RS and positive 
serologic results had development of ulcers in 15.5 % 
of patients (27.7% of  the long-term follow-up 
group), but amputations were rare. Almost all of  
these patients either had a CTD initially or had 
development of one during follow-up. 
In patients with obstructive RS, progression to 
ulceration and amputation was the same regardless of 
whether serologic abnormalities were present. Ulcer- 
ations were present in approximately 50% of each 
group, and phalangeal amputations were required in 
10% to 20%. The reasons for ulcerations and 
amputations were different in these two groups. 
Patients with positive serologic results most likely 
had a CTD, of which scleroderma was particularly 
virulent. Patients with negative serologic results were 
more likely to have Buerger's disease, atherosclerosis, 
or rapid onset digital artery obstruction from a 
variety of causes, most frequently hypersensitivity 
angiitis, a hypercoagulable state, or digital artery 
emboli from a proximal source. In the patient group 
studied, patients in the obst,sero + and obst,sero- 
groups had a similar outcome. 
Interestingly, no differences were noted between 
the group as a whole and those monitored longer 
than 10 years in the development of ulcerations and 
the need for digital or phalangeal amputations. This 
suggests that these are problems that arise early in the 
course of the disease. If patients have had RS for 
greater than 10 years and have not had problems with 
ulcerations or amputations, in our experience it is 
unlikely that they will have subsequent development 
of them. 
Patients with RS frequently are evaluated with 
similar symptoms regardless of  the underlying cause. 
For most of these patients, the symptoms are easily 
controlled with minimal intervention and with rare 
adverse sequelae. Clearly, however, a subset of pa- 
tients will have development of  more severe symp- 
toms and may require phalangeal amputations. The 
early ability to predict which patients will fall into 
these categories is of considerable importance for pa- 
tient counselling. Because our university is a tertiary 
care center that is frequently referred the most severe 
cases, it is unclear whether our overall experience 
reflects that of the general population. However, it 
does appear that categorization of patients into the 
above-mentioned groups at the time of initial presen- 
tation does provide both the patient and the referring 
physician with important prognostic information. 
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DISCUSSION 
Dr. John W. Joyce (Rochester, Minn.). The study is 
best approached as an historical contimmm. In describing 
both local asphyxia nd gangrene, Raynaud identified our 
charge of separating functional from obstructive disease 
and a benign from a destructive course. 
In 1932 Allen and Brown 2~ used clinical observations 
in tile first 2 years to separate a benign, primary Raynaud's 
disease from Raynaud's phenomenon asa result of other 
causes, most commonly scleroderma. Their concept re- 
mains valid, but their terminology has always been 
cumbersome. In the 1950s and 1960s, late crossover f om 
the primary group was noted to increase by Gifford and 
Hines 21 and others as our knowledge of CTDs matured. 
The last three decades have more fully defined hema- 
tologic and immunologic mechanisms. Angiography and 
the vascular laboratory provide accurate measurement of 
spasm and of obstruction. All are incorporated in this 
study. It has the broadest base extant, it is prospective, and 
it has excellent~ 
I want to condense these extensive data into three 
useful clinical groupings. The nonobstructive s ronegative 
group is the largest, and it documents the existence of a 
primary, benign RS. Only 2% later cross over to other 
secondary causes, and many of these are identified as 
coincidental events in the text. 
The seropositive group, with or without obstruction, 
declares econdary Raynaud's, with a high incidence of 
CTD initially and later, and it defines other syndromes 
whose behavior and treatment is quite possible. This group 
requires regular follow-up because of significant late 
crossover. 
Finally, the patients in the obst,sero- group are 
predominantly male, have a high incidence of requiring 
amputation, and they have the broadest spectrum of causes 
clearly outlined in the text. Many of these are common to 
the vascular surgical practice. Both a vigorous initial 
investigation and regular follow-up are necessary for the 
group. 
Does your experience include drugs, thoracic outlet 
syndromes, and occupational palmar disease as causes of 
Raynaud's phenomenon? 
You use the term atherosclerosis ina generic sense. Could 
you define the specific lesions uch as aneurysms, proximal 
disease, macroemboli, and microemboli that might be 
responsible? 
Do you have any data defining the effect of cessation of 
tobacco use on the course of RS? Would you comment on 
the value of nail bed microscopy in the differentiation of
secondary RS still commonly used in Europe? 
Dr. Gregory J. Landry. With respect to the question 
regarding drugs, thoracic outlet syndrome, and palmar 
occupational occlusive disease, our experience indicates 
that patients with all of the above-mentioned disorders are 
rare and therefore were not included in our study. 
The term atherosclerosis was applied to patients with 
obstructive RS with any type of generalized atherosclerosis 
in whom no other cause of digital artery obstruction could 
be detected. 
With regard to cessation of tobacco use, we recognize 
that patients with obstructive RS from causes such as 
Buerger's disease and atherosclerosis benefi~ from cessation- 
of tobacco use. We are not aware of any connection 
between patients with generalized vasospastic RS and 
history of smoking. 
Nail bed microscopy has been used by many people to 
evaluate patients for the development of scleroderma. We 
are not aware that nail bed microscopy can be used for other 
types of CTDs other than scleroderma, however, nor can be 
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it be used for patients with other types of obstructive RS 
such as Buerger's disease and atherosclerosis. In centers 
where this technology is available, it has been used with 
success; however, we do not perform this technique at our 
institution. 
Dr. Geun-Eun Kim (New York, N.Y.). Did the 
patient who eventually had development of CTD during 
your follow-up receive steroid treatment? As you know, 
steroids can affect arterial wall lesion beneficially or 
adversely. 
Dr. Landry. I 'm not aware whether patients were 
treated with steroids among the patients with CTDs. Many 
of these patients are seen in conjunction with the rheuma- 
tologists and internists. Our specific duty is to treat their 
symptoms of RS, and I'm not aware of the percentages of
patients with CTDs who were treated with steroids. 
Dr. Harry B. Abrarnowitz (Jerusalem, Israel). Be- 
cause the critical separation is between the spastic and the 
obstructive group, other than stating that you're using 
blood pressure studies and plethysmographic studies, 
what specifically are you using for your noninvasive 
determination? 
Dr. Landry. With regard to digital blood pressures, we 
regard a patient as having obstructive KS if there is a 
difference greater than 20 mm Hg between the brachial and 
digital blood pressure. 
With regard to digital plethysmography, we looked for 
dampening in the plethysmographic waveforms, specifi- 
cally with delayed upstroke and blunting of the peak of the 
waveform. 
Dr. Jack L. Cronenwett (Lebanon, N.H.). It's been 
said that ulcers never develop in patients in the spast,sero - 
group, and even in this series it rarely happened. But why 
did 5% have development of ulceration? 
Dr. Landry. We too were quite curious about why any 
of these patients had any adverse sequelae, and we studied 
this group of patients quite extensively and found that these 
patients went on to have development of some type of an 
obstructive process later in the course of their disease, 
specifically either Buerger's disease, some type of athero- 
sclerotic or embolic lesion, or some other type of obstruc- 
tive process that was not present at their initial evaluation. 
It may actually have been present but was not detected with 
our vascular laboratory methods. So in short, these are 
patients who subsequently went on to have development of
some type of obstructive process that was not detected 
initially. 
Dr. Thomas L. Whitsett (Oklahoma City, Okla.). 
Many patients are said to have RS who have some other 
type of vasospastic phenomenon. What criteria did you use 
to include these people in that category? 
Dr. Landry. We consider all patients admitted with 
either cold- or stressed-induced symptoms of digital artery 
ischemia as having RS. Approximately 90% of these 
patients will have their symptoms verified by a Nielsen test. 
We find that 10% of these patients, however, will not have 
a positive Nielsen test result; but because of the nature of 
their symptoms, we include them in the classification of 
patients with vasospastic KS. 
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